SGRY Quote, Financials, Valuation and Earnings

Encompass Health has a net margin of -4.12% compared to Surgery Partners's net margin of 8.01%. Surgery Partners's return on equity of -1.76% beat Encompass Health's return on equity of 17.39%.

Surgery Partners has a consensus price target of $34.02, signalling upside risk potential of 60.76%. On the other hand Encompass Health has an analysts' consensus of $116.75 which suggests that it could grow by 26.13%. Given that Surgery Partners has higher upside potential than Encompass Health, analysts believe Surgery Partners is more attractive than Encompass Health.

Surgery Partners has a beta of 2.585, which suggesting that the stock is 158.5% more volatile than S&P 500. In comparison Encompass Health has a beta of 0.900, suggesting its less volatile than the S&P 500 by 10.002%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Encompass Health offers a yield of 0.69% to investors and pays a quarterly dividend of $0.17 per share. Surgery Partners pays -- of its earnings as a dividend. Encompass Health pays out 17.16% of its earnings as a dividend. Encompass Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Surgery Partners quarterly revenues are $770.4M, which are smaller than Encompass Health quarterly revenues of $1.4B. Surgery Partners's net income of -$31.7M is lower than Encompass Health's net income of $108.2M. Notably, Surgery Partners's price-to-earnings ratio is -- while Encompass Health's PE ratio is 22.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.89x versus 1.81x for Encompass Health. Usually stocks with elevated PS ratios are considered overvalued.

Healthcare Services Group has a net margin of -4.12% compared to Surgery Partners's net margin of 3.28%. Surgery Partners's return on equity of -1.76% beat Healthcare Services Group's return on equity of 10.94%.

Surgery Partners has a consensus price target of $34.02, signalling upside risk potential of 60.76%. On the other hand Healthcare Services Group has an analysts' consensus of $13.60 which suggests that it could grow by 17.65%. Given that Surgery Partners has higher upside potential than Healthcare Services Group, analysts believe Surgery Partners is more attractive than Healthcare Services Group.

Surgery Partners has a beta of 2.585, which suggesting that the stock is 158.5% more volatile than S&P 500. In comparison Healthcare Services Group has a beta of 0.563, suggesting its less volatile than the S&P 500 by 43.743%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Healthcare Services Group offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners pays -- of its earnings as a dividend. Healthcare Services Group pays out -- of its earnings as a dividend.

Surgery Partners quarterly revenues are $770.4M, which are larger than Healthcare Services Group quarterly revenues of $428.1M. Surgery Partners's net income of -$31.7M is lower than Healthcare Services Group's net income of $14M. Notably, Surgery Partners's price-to-earnings ratio is -- while Healthcare Services Group's PE ratio is 16.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.89x versus 0.50x for Healthcare Services Group. Usually stocks with elevated PS ratios are considered overvalued.

Kindly MD has a net margin of -4.12% compared to Surgery Partners's net margin of -156.54%. Surgery Partners's return on equity of -1.76% beat Kindly MD's return on equity of -201.03%.

Surgery Partners has a consensus price target of $34.02, signalling upside risk potential of 60.76%. On the other hand Kindly MD has an analysts' consensus of -- which suggests that it could fall by --. Given that Surgery Partners has higher upside potential than Kindly MD, analysts believe Surgery Partners is more attractive than Kindly MD.

Surgery Partners has a beta of 2.585, which suggesting that the stock is 158.5% more volatile than S&P 500. In comparison Kindly MD has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kindly MD offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners pays -- of its earnings as a dividend. Kindly MD pays out -- of its earnings as a dividend.

Surgery Partners quarterly revenues are $770.4M, which are larger than Kindly MD quarterly revenues of $647.9K. Surgery Partners's net income of -$31.7M is lower than Kindly MD's net income of -$1M. Notably, Surgery Partners's price-to-earnings ratio is -- while Kindly MD's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.89x versus 2.86x for Kindly MD. Usually stocks with elevated PS ratios are considered overvalued.

The Oncology Institute has a net margin of -4.12% compared to Surgery Partners's net margin of -16.13%. Surgery Partners's return on equity of -1.76% beat The Oncology Institute's return on equity of -163.45%.

Surgery Partners has a consensus price target of $34.02, signalling upside risk potential of 60.76%. On the other hand The Oncology Institute has an analysts' consensus of -- which suggests that it could grow by 541.64%. Given that The Oncology Institute has higher upside potential than Surgery Partners, analysts believe The Oncology Institute is more attractive than Surgery Partners.

Surgery Partners has a beta of 2.585, which suggesting that the stock is 158.5% more volatile than S&P 500. In comparison The Oncology Institute has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Surgery Partners has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. The Oncology Institute offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Surgery Partners pays -- of its earnings as a dividend. The Oncology Institute pays out -- of its earnings as a dividend.

Surgery Partners quarterly revenues are $770.4M, which are larger than The Oncology Institute quarterly revenues of $99.9M. Surgery Partners's net income of -$31.7M is lower than The Oncology Institute's net income of -$16.1M. Notably, Surgery Partners's price-to-earnings ratio is -- while The Oncology Institute's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Surgery Partners is 0.89x versus 0.06x for The Oncology Institute. Usually stocks with elevated PS ratios are considered overvalued.